On Monday, Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) was -3.87% drop from the session before settling in for the closing price of $0.70. A 52-week range for LXRX has been $0.28 – $2.45.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 600.60% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 42.06%. With a float of $180.38 million, this company’s outstanding shares have now reached $361.49 million.
In an organization with 103 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 97.55%, operating margin of -634.2%, and the pretax margin is -644.78%.
Lexicon Pharmaceuticals Inc (LXRX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Lexicon Pharmaceuticals Inc stocks. The insider ownership of Lexicon Pharmaceuticals Inc is 50.33%, while institutional ownership is 34.49%. The most recent insider transaction that took place on Aug 15 ’24, was worth 480,000.
Lexicon Pharmaceuticals Inc (LXRX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 42.06% per share during the next fiscal year.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Trading Performance Indicators
You can see what Lexicon Pharmaceuticals Inc (LXRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.44. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.64, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.28 in one year’s time.
Technical Analysis of Lexicon Pharmaceuticals Inc (LXRX)
Let’s dig in a bit further. During the last 5-days, its volume was 3.57 million. That was inferior than the volume of 12.28 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 42.59%. Additionally, its Average True Range was 0.07.
During the past 100 days, Lexicon Pharmaceuticals Inc’s (LXRX) raw stochastic average was set at 48.63%, which indicates a significant increase from 26.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 77.98% in the past 14 days, which was lower than the 192.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5016, while its 200-day Moving Average is $1.0745. However, in the short run, Lexicon Pharmaceuticals Inc’s stock first resistance to watch stands at $0.7102. Second resistance stands at $0.7465. The third major resistance level sits at $0.7760. If the price goes on to break the first support level at $0.6444, it is likely to go to the next support level at $0.6149. The third support level lies at $0.5786 if the price breaches the second support level.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Key Stats
There are 361,492K outstanding shares of the company, which has a market capitalization of 244.75 million. As of now, sales total 31,080 K while income totals -200,400 K. Its latest quarter income was 26,550 K while its last quarter net income were -33,770 K.
